A Phase II Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of Maintenance IT-101 in Platinum Sensitive Ovarian Cancer Patients Who Received 4-6 Cycles of a 2nd Line Platinum-Based Regimen Without Disease Progression

Trial Profile

A Phase II Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of Maintenance IT-101 in Platinum Sensitive Ovarian Cancer Patients Who Received 4-6 Cycles of a 2nd Line Platinum-Based Regimen Without Disease Progression

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Camptothecin (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Mar 2012 Company (Cerulean Pharma) added as trial sponsor as reported by ClinicalTrials.gov.
    • 27 Mar 2012 Company (Cerulean Pharma) added as trial sponsor as reported by ClinicalTrials.gov.
    • 09 Jun 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top